Biomind Labs Shareholders Back All Resolutions, Reaffirm Leadership at AGM
Biomind Labs Announces C$2.52M Private Placement
Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 With Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood
Biomind Labs Announces Revocation of Cease Trade Order
Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board
Biomind Labs Inc: INTERIM MDA AMENDED EN
Biomind Labs Inc: MDA AMENDED EN
Biomind Labs Inc: MDA EN
Biomind Labs Inc: AUDITED ANNUAL FINANCIAL STATEMENTS EN
Biomind Labs Inc: INTERIM MDA EN
Biomind Labs Inc: INTERIM FINANCIAL STATEMENTSREPORT EN
Biomind Labs Inc: AB FORM 13-501F1 (CLASS 1 AND 3B REPORTING ISSUERS - PARTICIPATION FEE)
Biomind Labs Inc: ON FORM 13-502F1 (CLASS 1 AND 3B REPORTING ISSUERS - PARTICIPATION FEE)
Biomind Labs Inc: AUDITED ANNUAL FINANCIAL STATEMENTS - ENGLISH
Biomind Labs Inc: MD&A - ENGLISH
Biomind Labs Inc: INTERIM FINANCIAL STATEMENTS/REPORT - ENGLISH